HOMAGE
Heart OMics in AGEing
| Coordinatore | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 17˙673˙627 € |
| EC contributo | 12˙000˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-02-01 - 2019-01-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | coordinator | 1˙655˙000.00 |
| 2 |
ACS BIOMARKER BV
Organization address
address: OXFORDLAAN 70 contact info |
NL (MAASTRICHT) | participant | 2˙274˙400.00 |
| 3 |
UNIVERSITEIT MAASTRICHT
Organization address
address: Minderbroedersberg 4-6 contact info |
NL (MAASTRICHT) | participant | 925˙000.00 |
| 4 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 825˙000.00 |
| 5 |
FONDATION TRANSPLANTATION
Organization address
address: rue de la Brot 4 contact info |
FR (St Apollinaire) | participant | 750˙000.00 |
| 6 |
Randox Clinics Limited
Organization address
address: Diamond Road 34 contact info |
UK (Crumlin) | participant | 750˙000.00 |
| 7 |
UNIVERSITY OF HULL
Organization address
address: COTTINGHAM ROAD contact info |
UK (HULL) | participant | 725˙600.00 |
| 8 |
MOSAIQUES DIAGNOSTICS GMBH
Organization address
address: Mellendorfer Strasse 7-9 contact info |
DE (HANNOVER) | participant | 700˙000.00 |
| 9 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Organization address
address: BELFIELD contact info |
IE (DUBLIN) | participant | 700˙000.00 |
| 10 |
INSERM - TRANSFERT SA
Organization address
address: Rue Watt 7 contact info |
FR (PARIS) | participant | 450˙000.00 |
| 11 |
MEDIZINISCHE HOCHSCHULE HANNOVER
Organization address
address: Carl-Neuberg-Strasse 1 contact info |
DE (HANNOVER) | participant | 400˙000.00 |
| 12 |
Medizinische Universitaet Graz
Organization address
address: AUENBRUGGERPLATZ 2 contact info |
AT (GRAZ) | participant | 375˙000.00 |
| 13 |
FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA
Organization address
address: AVENIDA DE PIO XII 55 contact info |
ES (PAMPLONA) | participant | 310˙000.00 |
| 14 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | participant | 310˙000.00 |
| 15 |
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
Organization address
address: KEPPEL STREET contact info |
UK (LONDON) | participant | 300˙000.00 |
| 16 |
ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
Organization address
address: Via Giuseppe La Masa 19 contact info |
IT (MILANO) | participant | 200˙000.00 |
| 17 |
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
Organization address
address: STATE STREET 35 contact info |
US (ALBANY NY) | participant | 159˙433.51 |
| 18 |
UNIVERSITY OF GLASGOW
Organization address
address: University Avenue contact info |
UK (GLASGOW) | participant | 150˙000.00 |
| 19 |
EMORY UNIVERSITY NON PROFIT CORP
Organization address
address: Clifton Road, NE, 4th Floor 1599 contact info |
US (Atlanta) | participant | 40˙566.49 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'As more people survive into old age, the prevalence of heart failure (HF), one of the most common and debilitating diseases in older people, will rise still further. Delaying or preventing HF will have great benefit to those at personal risk, their families, society and the economy. HOMAGE aims to provide a biomarker (BM) approach that will a) help identify i. patients at high risk of developing HF before the onset of symptoms and ii. subsets of patients who are more likely to respond to specifically targeted therapies (personalized medicine). In available cohorts, we will identify the most promising ‘omics-based BM profiles for the pre-symptomatic diagnosis and future prediction of HF in patients at risk. The predictive value of the BMs for other co-morbidities commonly associated with HF and ageing will also be investigated. Furthermore, in a prospective trial, we will investigate the potential for targeting preventive therapy at patients with the greatest likelihood of response and the lowest risk of adverse effects. Our selection of innovative ‘omics-based BMs is based on knowledge of biological pathways of the disease, which may facilitate identification of ‘Biotargets’ for future therapies. On the economic side, HOMAGE will act as an economic catalyst for European SMEs in the field of cardiovascular and ageing BMs, estimated to peak annual turnovers of up to 800 M€.'